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Abstract: Thyroid hormones (THs) are important regulators of cell physiology. They are essential for the normal devel-
opment and growth of mammals, especially for the neural differentiation and the regulation of the metabolism and the 
immune system. THs also induce the proliferation of several cell types. In human and murine T cell lymphomas (TCL) 
this effect involves the participation of genomic and nongenomic mechanisms as it was described by the use of free THs 
and non-cell permeable THs coupled to agarose (TH-ag). The classic actions of thyroid hormones involve the alteration of 
gene transcription via specific nuclear receptors. The discovery of other effects, independent of this classic mechanism, 
characterizes a new and non-classic mechanism that involves different signaling pathways. Both, free THs and TH-ag, ac-
tivate protein kinase C, extracellular signal-regulated kinases and NF-kB and they increase the intracellular calcium lev-
els. However, only the preincubation of T cells with free THs leads to an increased intracellular content of signaling en-
zymes. T lymphomas display high expression levels of both, the TH nuclear receptors (TRs) and the putative membrane 
receptor for THs, the integrin V3, which has been demonstrated to be responsible for THs non-genomic actions. Here, 
we reviewed the mechanisms involved in THs modulation of the lymphocyte physiology, analyzing the interplay between 
genomic and nongenomic actions in T cells and its contribution in the development of lymphomas. 
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INTRODUCTION 
Classical and Non-Classical Pathways of Thyroid  
Hormone Actions 
The thyroid hormones (THs), triiodothyronine (T3) and 
thyroxine (T4), modulate several physiological processes 
and are critical for the growth, development, differentiation 
and maintenance of metabolic homoeostasis [1]. 
THs are synthesized in the thyroid gland follicles through the 
iodination of tyrosine residues in thyroglobulin [2, 3]. The 
pituitary gland secretes thyroid stimulating hormone (TSH) 
in response to the feedback from circulating THs. TSH, in 
turn, regulates the iodide uptake mediated by the so-
dium/iodide symporter in the thyroid follicles and stimulates 
the synthesis and secretion of THs [4]. 
THs are hydrophobic molecules that enter the cell by 
specific transporters, such as the monocarboxylate (MCT) 
family and organic anion transporters (OATPs). Experiments 
in murine models of MCT8 and Oatp1c1 deficiency demon-
strate that these transporters are required to regulate the THs 
secretion [5] and the metabolism and action of THs in the 
mouse brain [6]. 
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Iodothyronine deiodinases can locally increase or de-
crease THs signaling in a temporal and tissue specific man-
ner, independent of the changes in TH serum concentrations. 
Deiodinases type 1 and 2 (D1 and D2) are active deiodinases 
in the conversion of T4 to T3, while the type 3 deiodinase 
(D3) is an inactivating deiodinase. In humans, the T4 pro-
hormone is deiodized by the D2 activity to give the active 
form, T3, but in other mammals, such as rodents, the conver-
sion of T4 into T3 is mediated mainly by the action of D1 
[7]. Local activation of T3 at the tissue level is an important 
mechanism for the regulation of THs action [8]. The D3-
mediated inactivation of T4 to form reverse T3 (rT3), is also 
an important regulator of the tissue levels of T3, particularly 
within the thyroid axis and for the development of sensory 
systems [9].  
The effects of THs are mediated mainly by the classical 
signaling pathways. This mechanism requires the THs inter-
action with its nuclear receptor (TR), which acts as a tran-
scription factor. It directly interacts with specific DNA se-
quences on the promoter of thyroid hormone responsive 
element (TRE), and regulates the transcription of a wide 
range of target genes [10, 11, 12]. The TRs are encoded by 
two genes, TR and TR [13], with distinct splice products. 
There are different expression patterns of these isoforms 
during the development or in adult tissues [1, 14]. The TR1 
is predominantly expressed in brain, heart and skeletal mus-
cle, the TR2 is expressed primarily in the brain, retina and 
inner ear, and TR3 is expressed in kidney, liver, and lung 
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[14]. TR2 and TR3 isoforms are splice truncated forms 
and are not active. TR mutations have been identified in 
several cancers, such as hepatocellular carcinoma, renal cell 
carcinoma, erythroleukemias, and thyroid cancer [15, 16]. 
The interaction of the ligand-TR complex with TRE se-
quences induces the recruitment of coactivators and gene 
transcription [17]. The mechanisms involved in TH actions 
are complex and highly regulated by the expression of tis-
sue-specific TH transporters and deiodinases, the expression 
and distribution of the TR isoforms and by the interactions 
with coactivators and corepressors [14, 18]. In addition, in 
some cases, the signals triggered by THs can be involved in 
a cross-talk with other signaling pathways. Thus, an impor-
tant TH action is to potentiate or increment other transduc-
tion pathways [19-21]. The broad range of genes whose ex-
pression is modified by thyroid status, includes the Na/K 
ATPase, the R1 adrenergic receptor, the LDL receptor, the 
factor for adipocyte differentiation, the mitochondrial AT-
Pase, the HMG-CoA reductase, the bone morphogenetic 
protein 1 and the nerve growth factor, among others [21, 22]. 
THs regulate the metabolism of lipids [23], carbohydrates 
[24] and exert actions on cardiovascular [25], nervous [26] 
and immune [27, 28] systems.  
The THs also exert actions on cell physiology through 
nongenomic mechanisms that do not involve the direct regu-
lation of gene transcription by TRs [29]. Several studies have 
identified the integrin v3 as specific TH receptor in 
plasma membrane, responsible for non-genomic actions of 
thyroid hormones [30] in several tissues, such as blood ves-
sels and heart [31]. Studies on human cancer cell lines, such 
as breast adenocarcinoma [32], papillary and follicular thy-
roid carcinomas [33], glioma [34] and lung carcinoma [35], 
showed that the treatment with physiological concentrations 
of T3 and T4 leads to the activation of extracellular-
regulated kinases 1/2 (ERK1/2). This subsequently induces 
the cell proliferation as evidenced by an accumulation of 
PCNA. These effects were blocked by the treatment of cells 
with RGD, a peptide that prevents the binding of THs to the 
integrin v3.  
Therefore, THs bind to v3 integrin in plasma mem-
brane and initiate nongenomic actions on tumor cell prolif-
eration mediated by ERK1/2. Phosphatidylinositol 3-kinase 
(PI3K) is also involved in nongenomic actions of THs, such 
as angiogenesis, but apparently cannot lead to tumor cell 
division [36]. The presence of the integrin v3 on vascular 
and tumor cells explains the proangiogenic and proliferative 
effects of THs on certain cancer cells, including gliomas 
[14]. 
Direct Action of THs on TCL Cells Involves Both  
Genomic and Nongenomic Actions 
Studies using free THs and non-cell permeable THs cou-
pled to agarose (TH-ag), have shown that both, genomic and 
nongenomic actions of THs, contribute to the proliferation of 
human and murine T lymphoma cell lines (TCL), thus indi-
cating the participation of a membrane receptor for THs 
(mTR) in these cells [37, 38, 39]. The nongenomic signaling 
 
Fig. (1). Proposed Classical and non-classical thyroid hormone intracellular pathways involved in T lymphoma growth. Classical 
pathway of HTs actions: Free T3 or T4 hormones enter the cell cytoplasm, where T4 may be turned into T3 by deiodinases. Then, T3 enters 
the nucleus, interacts with the thyroid receptors and binds to the promotor secuences activating the transcription of specific genes related to 
the survival, growth and thyroid hormones receptors (nuclear and membrane). Non-classical pathways: free or agarose coupled THs (THs-
ag) interacts with integrin V3 in the plasma membrane and triggers PKC activation downstreamn esphingomielinases (SMases). Active 
PKC induces ERK phosphorylation and NFKB activation. Then, NFKB activates the transcription of specific genes.  
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cascade triggered by THs through the mTR in murine TCL, 
involves the rapid translocation of protein kinase C  (PKC) 
isoform to cell membranes, mediated by the action of sphin-
gomielinases [40]. PKC activation is essential for the pro-
liferation and survival of T cell lymphomas [37] and other 
cell types. The PKC isoenzymes seem to be important cellu-
lar regulators in hematologic malignancies. Thus, also the 
inhibition of PKC in multiple myeloma cell lines was dem-
onstrated to suppress the signaling through the AKT path-
way, thus inhibiting the proliferation and inducing apoptosis 
[41]. In addition, THs nongenomically induce the phos-
phorylation of extracellular-signal-regulated kinases 
(ERK1/2) and the activation of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-B) on both, murine 
and human TCL cell lines. Both effects seem to be triggered 
downstream PKC activation [40]. Similarly, in HEK293A 
cells, it was observed that the participation of PKC is essen-
tial for ERK2-mediated activation of NF-B and iNOS, 
promoting cell survival [42]. Furthermore, both free THs and 
TH-ag increased the protein and mRNA levels of the TH 
nuclear receptor TR1 in murine TCLs, but the inducible 
nitric oxide synthase (iNOS) protein and mRNA levels as 
well as its enzymatic activity were only increased by free 
hormones [40].  
We have recently demonstrated that integrin v3 is the 
mTR in human TCL cell lines. Proliferative actions of THs 
were demonstrated in a panel of 9 cell lines of TCL repre-
senting the different subtypes of the human pathology. These 
effects were abrogated by the RGD peptide and were not 
observed when knocking down the integrin v3 with 
siRNA against both v3 integrins [39]. 
These contributions indicate that THs are capable of sus-
tained TCL proliferation by both classical and non-classical 
signaling pathways.  
The control of the cell cycle is the most important 
mechanism for the regulation of cell division. In several cell 
types, including TCL, THs can modulate the cell cycle, 
through the regulation of the levels of expression of cyclins, 
cyclin-dependent kinases and cell cycle inhibitors [43]. In rat 
GC pituitary cells, T3 induces the acceleration of the G1 
phase of the cell cycle leading to an increase of cell prolif-
eration [44]. In addition, the treatment of rat cardiomyocytes 
with T3 increases the expression levels of cyclin D1 and thus 
induces the cell cycle progression [45]. In accordance with 
these results, the increment of Cyclin D1 has been widely 
linked to the TH-mediated regulation of the cell cycle in 
various cell types [46-47].  
The cell division rate of TCLs is also increased by THs. 
This effect is mediated by the induction of the cyclins ex-
pression and the reduction of the expression levels of cyclin-
dependent kinases and tumor suppressor genes. In vitro stud-
ies have shown that the action of THs on cell division can 
lead to an exacerbation of cell cycle progression that could, 
eventually, induce cellular apoptosis as a result of the loss of 
checkpoint mechanisms and the inactivation of signaling 
pathways [40]. However, although solid tumor TCLs grow-
ing in hyperthyroid mice showed an increased number of 
apoptotic cells, this is not related to remission [43]. This 
suggests that the in vivo effects of THs on the tumor growth 
are probably modulated by other factors present in the tumor 
microenvironment.  
Another important process for tumor growth and devel-
opment is the production of angiogenic factors. These factors 
allow the vascularization of tumor tissue. In this regard, it 
was shown that THs, acting via the integrin v3, induce 
multiple vascular growth factor receptors as well as their 
ligands, such as vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), platelet-derived 
growth factor (PDGF) and epidermal growth factor (EGF), 
as well as angiogenic chemokines [48]. THs may also in-
crease the activity of bradykinin and angiotensin II, thus con-
tributing to the vascularization [48]. 
In human breast cancer cells, the inhibition of integrin 
v3 by tetraiodothyroacetic acid (TETRAC) blocked the 
nongenomic proliferative and proangiogenic actions of THs 
through the inhibition of the angiogenic effects of VEGF and 
bFGF. These cells also showed an increase in the pro-
apoptotic genes expression, demonstrating that the THs are 
essential for cell survival [49, 50]. On human TCLs, TH-ag 
induce the expression of VEGF genes and the VEGF produc-
tion, effects that were impaired when knocking-down the 
integrin V3 expression with the corresponding siRNA, 
thus confirming that these mechanisms are also present in 
malignant T cells [39]. In addition, the integrin v3 engages 
in crosstalk with the VEGF and bFGF receptors, so THs may 
favor this interaction [51]. 
Thyroid Status Modulates in vivo Growth of TCL  
The direct actions of THs are generally studied in iso-
lated cells with the addition of exogenous hormones. This 
does not precisely reproduce what happens in the intact or-
ganism. As THs stimulate the proliferation of various cell 
lines and induce the production of angiogenic factors, this 
could contribute to the tumor growth in vivo in hyperthyroid 
subjects. 
Hyperthyroidism has been described as a risk factor for 
the development of ovarian [52], pancreas [53], lung and 
prostate [54] cancers. On the other hand, clinical hypothy-
roidism is associated with greater survival in various types of 
malignant processes, but the mechanisms involved are un-
known [55]. Cristofanilli et al. [56] have described a reduced 
incidence of mammary carcinoma in hypothyroid patients, 
and Hercbergs [57] has suggested that hypothyroidism could 
contribute to spontaneous or therapy-induced tumor regres-
sion. However, other authors describe hypothyroidism as a 
risk factor for the development of liver and breast cancer [58, 
59]. 
Controversial effects of thyroid status in tumor develop-
ment could be related to the known regulation that THs exert 
on the immune response [60]. In vivo studies have shown the 
modulatory action of thyroid status on the growth of TCL. T 
lymphoma cells, growing as solid tumors in hyperthyroid 
mice, exhibited a higher growth rate and a greater volume 
than euthyroid or hypothyroid animals. This was accompa-
nied by increased levels of PCNA. In addition, tumor sec-
tions from these tumors showed high vascularization, low 
levels of necrosis and increased proliferative indexes despite 
displaying high apoptosis [43]. Deregulation of the balance 
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between apoptosis and proliferation is a frequent feature in 
several human lymphoproliferative syndromes that is related 
to tumor aggressiveness [61]. Consistent with these findings, 
Martínez Iglesias et al. [62] observed a smaller tumor devel-
opment in hypothyroid mice inoculated with xenografts of 
human hepatocarcinoma and breast cancer lines. In addition, 
the volume and vascular support of xenografts of human 
pancreatic, kidney, lung, and breast cancers are downregu-
lated by inhibition of the integrin v3 by TETRAC [50]. 
Differential expression of cell cycle regulatory proteins 
was also observed in murine models of TCL with different 
thyroid status. The levels of cyclins D1 and D3 were aug-
mented in TCL tumors of hyperthyroid animals, whereas the 
cell cycle inhibitors p16/INK4A and p27/Kip1 and the tumor 
suppressor p53 were increased in these mice [43]. Cyclin D1 
and D3 has been widely linked to the T-cell lymphomagene-
sis and several authors have associated its positive regulation 
with a poor prognosis in patients with lymphoblastic lym-
phoma [63-67]. Negative regulation of the tumor suppressor 
genes expression, such as PTEN [68], Rb [64, 65, 69] and 
p53 [64, 70, 71] has been described as important factors for 
the development of lymphoid malignancies. TCL tumors 
growing in hyperthyroid mice also showed increased ge-
nomic expression levels of cyclin E [43]. Increased levels of 
this cyclin, together with a reduction in p27/Kip1 levels, has 
also been described in T cell lymphomas [72-74]. These 
findings are consistent with previous studies on liver regen-
eration in hyperthyroid rats, that showed increased expres-
sion levels of cyclins D1, E and A, and decreased levels of 
p16/INK4A and p27/Kip1 [75]. 
Several studies have shown that THs induce angiogenesis 
in normal and tumor tissues. Induction of angiogenesis me-
diated by THs has been shown in brain through the action of 
VEGF-1 and FGF-2 [76]. TCL growing in hyperthyroid 
mice, but not in hypothyroid mice, showed increased intra-
tumoral and peritumoral vasculogenesis [43].  
Also in hepatocytes, hepatoma cells and kidney and lung 
carcinomas an increased production of VEGF was observed, 
induced by the interaction of T3 with its nuclear receptor 
[77]. However, evidence suggests that the proangiogenic 
effect of THs is mediated by integrin v3. In this sense 
Bergh [30] has described T4-induced angiogenesis in a 
chicken chorioallantoic membrane angiogenesis model that 
was reversed by the pharmacologic or genomic inhibition of 
integrin v3. Davis et al. [78] also described in this model 
that T4-ag and T4 showed similar angiogenic effects. The 
interaction of THs with the integrin v3 induces the phos-
phorylation of ERK, activating several transcription factors 
that lead to an increase of angiogenic factors, such as FGF-2, 
VEGF, and Ang-2 [79]. In human TCL xenografts in immu-
nodeficient mice it was also demonstrated that the knock-
down of integrin V3, decreases tumor volume and vascu-
larization (Cayrol et al, 2014), strengthening the contribution 
of THs to angiogenesis also in TCL.  
CONCLUDING REMARKS 
THs are involved in the modulation of TCL proliferation 
in vitro and in vivo, through the induction of signaling path-
ways that involved both the TRs and the mTR in the integrin 
V3. Among the signals triggered via the integrin, the acti-
vation of sphingomyelinases, PKC, NF-B and ERK play a 
crucial role in TCL growth. These mechanisms also involve 
TH-mediated modulation of cell cycle regulators and angio-
genic factors. These results indicate that the integrin V3 
exerts a novel modulation of TCL pathophysiology and that 
its inhibition would be an effective treatment for TCL pa-
tients. 
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